News

Stuart McDougall, Quotient Sciences' Principal Research Fellow of Bioanalytical Services, contributes to the European Bioanalysis Forum Workshop on the Harmonized Implementation of the ICH M10 Guideline.

Ensysce Biosciences' PF614-MPAR, could be the industry's first overdose protection pain product, now entering a final Phase 1 study with Quotient Sciences.

John McDermott, Vice President of Scientific Consulting at Quotient Sciences, contributes to recent roundtable article with Drug Development & Delivery on 2023 trends.

Dr. Sarah Stevens, Senior Vice President & Head of Early Development & Late-Stage Commercial at Quotient Sciences, recently spoke with Raman Sehgal, host of the Molecule to Market podcast, about her career in the pharmaceutical industry and the differentiated drug development services that Quotient Sciences offers to customers.

HighTide Therapeutics, Inc. (“HighTide”), a globally integrated clinical-stage biopharmaceutical company focusing on novel multifunctional therapeutics for metabolic and digestive diseases, and Quotient Sciences, a drug development and manufacturing accelerator, have signed an agreement to support HighTide’s HTD1801 program.

Quotient Sciences Celebrates Grand Opening of New Drug Substance Facility with Official Ribbon Cutting at our Alnwick facility.